|
|
|
|
Patients who receive ticlopidine would experience two fewer initial strokes per hundred than those treated with aspirin.Life expectancy would be extended by approximately one-half month,and lifetime medical care costs(discounted at 5%)would increase by about$2300.The cost-effectiveness of ticlopidine,compared with aspirin,is estimated to range from$31,000 to$ 55,500 per quality-adjusted life-year gained as the utility of life after nonfatal stroke is assumed to vary from 0.75 to 0.95.Ticlopidine therapy to prevent stroke in high-risk patients is cost-effective by current standards of medical practice. |
|